| Cat. No. |
Product Name |
Information |
| PC-62261 |
JKA3 inhibitor 31
|
JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases. |
| PC-61818 |
PF-06700841 tosylate
|
PF-06700841 is a potent, selective TYK2/JAK1 kinase inhibitor that reduces IL-23 expression and directly attenuates IL-23 signaling via TYK2. |
| PC-61277 |
EXEL-8232
|
A potent and selective, orally bioavailable JAK2 inhibitor with IC50 of 2 nM. |
| PC-61264 |
NC1153
|
A Mannich base compound, selective and orally active JAK3 inhibitor that blocks IL-2-induced activation of JAK3 and downstream substrates STAT5a/b. |
| PC-61263 |
EP009
|
A selective, orally active JAK3 inhibitor that reduces IL-2-mediated JAK3 tyrosine phosphorylation with cellular IC50 of 10-20 uM. |
| PC-45873 |
Ruxolitinib S enantiomer
|
The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.. |
| PC-45647 |
JAK3-IN-1
|
JAK3-IN-1 is a potent and selective JAK3 inhibitor with IC50 of 4.8 nM. |
| PC-45817 |
Tofacitinib citrate
|
A potent, specific, orally active inhibitor of JAK3 with IC50 of 1 nM in cell-free assays. |
| PC-42802 |
WHI-P97
|
A potent, specific JAK3 inhibitor with Ki of 0.6-2.3 uM. |
| PC-42570 |
TG-101209
|
A potent, selective, orally bioavailable JAK2 inhibitor with IC50 of 6 nM. |
| PC-45875 |
Ruxolitinib sulfate
|
A potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively. |
| PC-45874 |
Ruxolitinib phosphate
|
A potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively. |
